MENU

Fox Chase Cancer Center News

Cosmesis was rated as good in 81 percent of trials of conventional excision, 74.6 percent of trials of EBRT, and 97.6 percent of trials of brachytherapy.
September 20, 2019

Cosmetic Satisfaction Similar for Radiation, Surgical Treatments of Non-Melanoma Skin Cancers

PHILADELPHIA (September 20, 2019) – Many of the most common treatment modalities for localized non-melanoma skin cancers resulted in similar cosmetic outcome and local control one year after treatment, according to a new study from researchers at Fox Chase Cancer Center.

September 15, 2019

Patient-Reported Quality of Life May Guide Treatment Decisions for Lower-Risk Prostate Cancer

CHICAGO (September 15, 2019) – New research from Fox Chase Cancer Center may help guide men with prostate cancer in selecting the appropriate type of short course radiation therapy to treat their disease.

“We wanted to investigate the relationship between severe lymphopenia and poor survival, and if they were linked, potentially alter treatment regimens.”
September 15, 2019

Severe Lymphopenia Linked With Worse Outcomes After Chemoradiation for Esophageal Cancer

CHICAGO (September 15, 2019) – Patients with esophageal cancer who experienced severe lymphopenia after undergoing chemoradiation were more likely to have their disease recur and were at greater risk for death, according to a new study from researchers at Fox Chase Cancer Center.

Fox Chase-Temple University Hospital Bone Marrow Transplant Program
September 13, 2019

Fox Chase Cancer Center Welcomes Michael Jay Styler

PHILADELPHIA (September 13, 2019) – Fox Chase Cancer Center hired Michael Jay Styler, MD, for the Department of Hematology/Oncology as an associate professor in the Bone Marrow Transplant Program.

September 11, 2019

Connolly Wins Rollman Award for Ovarian Cancer Research

Dr. Connolly is currently researching a subtype of ovarian cancer, high-grade serous carcinoma, in mouse models to understand why not all ovarian cancer arises in the ovary. Another project Connolly explores how a specific tool antibody may be developed into a therapeutic drug to kill ovarian cancer cells.Dr. Connolly is currently researching a subtype of ovarian cancer, high-grade serous carcinoma, in mouse models to understand why not all ovarian cancer arises in the ovary. Another project Connolly explores how a specific tool antibody may be developed into a therapeutic drug to kill ovarian cancer cells.

The award recognizes the achievements of outstanding alumni whose “personal lives, professional achievements, and community service exemplify the objectives of their alma mater.”
September 11, 2019

Jadwin Receives Alumni Award From Gwynedd Mercy

PHILADELPHIA (September 11, 2019) – Anne Jadwin, MSN, RN, AOCN, NE-BC, Vice President of Nursing Services and Chief Nursing Officer, was honored with the 2019 Distinguished Alumni Award from Gwynedd Mercy University. The award recognizes the achievements of outstanding alumni whose “personal lives, professional achievements, and community service exemplify the objectives of their alma mater.”

September 10, 2019

Marcin Chwistek, MD, Appointed Editor-in-Chief of AAHPM Quarterly

PHILADELPHIA (September 10, 2019) – Marcin Chwistek, MD, FAAHPM, director of the Pain and Palliative Care Program, has been appointed Editor-in-Chief of AAHPM Quarterly.

Andrews’ contribution to the study is his expertise in histone acetylation, by which DNA is made available for cellular processes.
September 9, 2019

Fox Chase Researcher Lands NCI Grant to Study Cancer Epigenetics

PHILADELPHIA (September 9, 2019) – Andrew J. Andrews, PhD, has been awarded a $33,348 grant from the National Cancer Institute for research attempting to determine the fundamental processes by which cancer cells can sense deficiencies in the production of essential metabolic components and adapt to overcome this and survive.

Pages

Connect with Fox Chase